Some breast tumor subtypes, including triple negative breast cancer (TNBC), are not responsive to endocrine and targeted therapies and currently, only 10-20% of TNBC patients benefit from immunosuppressive therapy targeting PD-1/PD-L1 [5]. This evidence concerns the gene CD274 and breast neoplasm.